Skip to main content

Text Size:

Contrast:

UKAOS Subgroups

 

The Treatment Toxicity Subgroup (TTSG)

UKAOS Subgroups are a group of people who share a common interest in a topic relevant to Urgent Cancer Care and work together to fulfil both individual and group goals. All subgroup members should be formally registered as UKAOS members.

This subgroup will be the topic advisory group within the UKAOS.

The UKAOS Treatment Toxicity subgroup focuses on the impact of anti-cancer therapies in the setting of acute oncology throughout the UK. This is an ongoing challenge both in terms of breadth of anti-cancer oncological therapies we are now using as standard of care and the wide range of toxicities related to those therapies.

Therapies are often used concurrently, and management of toxicities/problems is complex, with this in mind the group will provide an overarching view and include the following therapies in its remit:

  • Systemic Anti-Cancer Therapies side effects and toxicity recognition and management
  • Radiotherapy side effects
  • Symptom and Toxicity Management therapies administration and side effects

Aims of the sub-group 

  • The aim to build a multiprofessional group (including but not limited to clinicans, nurses, pharmacists and allied health professionals) who can bring expereince of different perspectives of anti-cancer therapies and the impact on acute oncology services.
  • This multi disciplinary professional group will strive to provide leadership, guidance and support for acute oncology teams across the UK and work collaboratively with acute oncology and other specialists to share knowledge and best practice to enhance the quality of acute cancer care.

The broad objectives of the sub-group are:

1.Education and training to support development of practice and improve the quality of learning and teaching:

  • Identification of learning gaps and furture requirements in the multiprofessional, multispeciality workforce
  • Development of standard induction materials to enable a good working knowledge of therapy toxicities and key learning points
  • Development and provision of learning materials that can be utilised by AOS teams to support specialities outside of oncology
  • Finding, collating, organising, and distributing knowledge to Subgroup members and the wider health care community.

2. Developing best practice:

  • to develop, validate, promote and disseminate best practice in the recognition, management and monitoring of anti-cancer treatment related side effects and toxicities.
  • Interface with other relevant national/internationa groups to collaborate on pathways relevant to anti-cancer treatment tocicity manamgement eg low risk neutropenia pathway, ambulatory toxicity management pathways

3. Problem solving:

  • to bring together expertise to address common challenges and solving a common problem, thus providing benefits to members and the wider health care community.

4. Innovation:

  • Horizon scanning to identify novel issues with the introduction of new theraputic agents and the associated knowledge requirements
  • Develop and disseminate guidance, information and training for the AOS community, oncology communites and our broader colleagues realting to the management of new and novel toxicities
  • Identifying opportunities for innovation and research.

5. Advocacy:

  • to ensure that UKAOS has an informed and productive role in the development and implementation of best practice in the management Anti-Cancer Therapy Toxicities.
  • Develop practice standards that will improve and maintain patients’ safety and quality of care and experience

Membership

This group is managed by a commitee drawn from members of UKAOS 

  • Co Chair -  Dr Caroline Wilson.  UKAOS Board Member
  • Co Chair - Dr Anna Olsen Brown
  • Secretary -

There is a core group of  10/14 UKAOS members providing representation from AO/SACT/Radiotherapy/Pharmacy and from the 4 nations.

We have a wider comminity of practice group that meets every virtually three months, to discuss current practice , share innovation and raise concerns and or suggestions for future projects.

If you would like to join the group, please complete an enquiry form on the UKAOS website, and we will respond. 

 

      The group governance structure and reporting.

TTSG.png

 

 

 

 

 Records:

  • Group terms of reference and governance can be found at this link
  • Minutes of the TTSG meetings can be found here 
  • Useful information and TTSG meeting presentations can be found here 

 

Group Activities: 

 
 

Feedback and Questions  

If you have any feedback or questions about the nursing group, please submit your enquiry here: Contact us :: UK Acute Oncology Society 

 We value your feedback and suggestions for improvement: If you would like to suggest additional content or report any broken/ out of date  links please complete a contact form and we will get in touch. 

 

Please note that you should always assume that the website group, society and authors /owners of any of these document’s links or guidance make no representations or guarantees as to the accuracy, completeness or adequacy of any of the content and make no warranties express implied or otherwise and cannot be held responsible for any liability, loss or damage whatsoever caused by the use of the content. You should always act within the limits of your competence and seek senior advice or support where appropriate. 
 

 

 

 

 

 

 

 

 

 

 

 

Megaphone1 with solid fill

 

Exciting News - this group is undergoing a refresh and will be launched shortly.

Please keep an eye on this page and we will update you regarding progress.   

 

This will be an overarching subgroup that will cover the acute side effects/ toxicities that may arise as a consequence of any of the full spectrum of systemic anti-cancer therapy treatments, and work to provide support and guidance for the health care teams supporting patients.

The aims of the subgroup are:

  • to work with the society members and relevant national groups and organisations to share information and highlight areas of best practice and areas of concern
  • to collaborate with national groups and organisations to produce/review acute oncology guidelines and guidance
  • to provide expert opinion relating to the management of treatment related toxicities to promote and support innovation and service development
  • to review, develop and share information and guidance relating to acute effects of new and evolving treatments 

The group will have key links with:

  • The UK Chemotherapy Board
  • UKONS Acute Oncology SACT Members Interest Group

If you would like to be involved in this group please complete an enquiry form on our contact us page